Haisikang: Innovative drug HSK39004 inhalation powder aerosol included in the Breakthrough Therapy Designation program

MetaMuskRat · 2026-04-08T16:53:17+00:00

People's Finance News, April 7 — Haishike (002653) announced on April 7 that HSK39004 Inhalation Powder has officially been included in the "Breakthrough Therapy Designation List" by the National Medical Products Administration's Center for Drug Evaluation (CDE). After being designated as a breakthrough therapy, HSK39004 Inhalation Powder is expected to receive priority review during the registration process, accelerating its market approval. HSK39004 is a new, independently developed targeted small-molecule inhibitor with proprietary intellectual property rights, intended for clinical use in the treatment of chronic obstructive pulmonary disease (COPD).

MetaMuskRat

2026-04-08 16:53:17

People’s Finance and News April 7 report: On April 7, Haisico (002653) announced that its HSK39004 inhalation powder mist was officially included in the “Breakthrough Therapy Varieties List” by the National Medical Products Administration’s Center for Drug Evaluation (CDE). After HSK39004 inhalation powder mist was included as a breakthrough therapy, it is expected to obtain priority review eligibility during the market application stage, accelerating the product’s listing. HSK39004 is a brand-new targeted small-molecule inhibitor independently developed by the company with independent intellectual property rights. It is intended for clinical treatment of chronic obstructive pulmonary disease.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes